Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

Cancer Research

Volumn 66, Issue 19, 2006, Pages 9646-9655

  Van Maerken, Tom ^a   Speleman, Frank ^a   Vermeulen, Joëlle ^a   Lambertz, Irina ^b   De Clercq, Sarah ^b   De Smet, Els ^a   Yigit, Nurten ^a   Coppens, Vicky ^a   Philippé, Jan ^a   De Paepe, Anne ^a   Marine, Jean Christophe ^b   Vandesompele, Jo ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LENTIVIRUS VECTOR; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL SURVIVAL; CYTOTOXICITY; DRUG MECHANISM; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE NUMBER; GENETIC ANALYSIS; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE MYC; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; SENESCENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL AGING; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; GENE DOSAGE; GENE TARGETING; GENES, MYC; GENES, P53; GENETIC VECTORS; HUMANS; IMIDAZOLES; NEOPLASM PROTEINS; NEUROBLASTOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750346173     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0792     Document Type: Article

References (44)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
2. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
3. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
4. Kohn KW, Pommier Y. Molecular interaction map of the p53 and Mdm2 logic elements, which control the Off-On switch of p53 in response to DNA damage. Biochem Biophys Res Commun 2005;331:816-27.
5. Barak Y, Juven T, Haffner R, Oren M. mdni2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
6. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
7. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
8. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
9. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004;3:419-21.
10. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-9.
11. Stuhmer T, Chatterjee M, Hildebrandt M. et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609-17.
12. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003;197:93-8.
13. Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol Pharmacol 2001;59:135-43.
14. Corvi R, Savelyeva L, Amler L, Handgretinger R, Schwab M. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. Eur J Cancer 1995;31A:520-3.
15. Corvi R, Savelyeva L, Breit S, et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995;10:1081-6.
16. Van Roy N, Forus A, Myklebost U, Cheng NC, Versteeg R, Speleman F. Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. Cancer Genet Cytogenet 1995; 82:151-4.
17. Carr J, Bell E, Pearson AD, et al. Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006;66:2138-45.
18. Thompson PM, Maris JM, Hogarty MD, et al. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 2001;61:679-86.
19. Slack A, Chen Z, Tonelli R, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 2005;102:731-6.
20. Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene 2000;19:232-40.
21. De Preter K, Speleman F, Combaret V, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002;15:159-66.
22. Pattyn F, Robbrecht P, De Paepe A, Speleman F, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res 2006;34:D684-8.
23. Vandesompele J, De Paepe A, Speleman F. Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR Anal Biochem 2002;303:95-8.
24. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
25. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001;61:8-13.
26. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
27. Gestblom C, Hoehner JC, Hedborg F, Sandstedt B, Pahlman S. In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas. Am J Pathol 1997;150:107-17.
28. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest 1996;75:659-75.
29. Pahlman S, Hoehner JC, Nanberg E, et al. Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 1995;31:A453-8.
30. Schramm A, Schulte JH, Astrahantseff K, et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005;228:143-53.
31. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
32. Slack A, Shohet JM. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Cell Cycle 2005;4:857-60.
33. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-99.
34. Balint E, Bates S, Vousden KH. Mdm2 binds p73α without targeting degradation. Oncogene 1999;18:3923-9.
35. Zeng X, Chen L, Jost CA, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999;19:3257-66.
36. Kojima T, Ikawa Y, Katoh I. Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors. Biochem Biophys Res Commun 2001;281:1170-5.
37. Little NA, Jochemsen AG. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 2001;20:4576-80.
38. Wang X, Arooz T, Siu WY, et al. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 2001;490:202-8.
39. Okada Y, Osada M, Kurata S, et al. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63α) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res 2002; 276:194-200.
40. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002;277:2674-81.
41. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-53.
42. Raza A, Preisler H, Lampkin B, et al. Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. Am J Hematol 1993;42:147-57.
43. Sidell N, Lucas CA, Kreutzberg GW. Regulation of acetylcholinesterase activity by retinoic acid in a human neuroblastoma cell line. Exp Cell Res 1984; 155:305-9.
44. Edsjo A, Lavenius E, Nilsson H, et al. Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment. Lab Invest 2003; 83:813-23.